Q-omics provides the consensus-scored RPS23P6 profile across patient tissues and cancer cell-line models. RPS23P6 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RPS23P6 is differentially expressed in 5, with the highest sampling consensus in STAD. Additionally, RPS23P6 RNA expression shows 14,802 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, STAD, and THYM as cancer lineages where RPS23P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS23P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS23P6 survival associations across molecular data types. RPS23P6 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS23P6 RNA expression–survival associations across cancer types. High RPS23P6 expression shows unfavorable associations in KIRC, UVM and THCA, but favorable associations in LUSC, READ and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RPS23P6 RNA expression.
This table summarizes RPS23P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS23P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS23P6 shows lower tumor expression in KICH and KIRC and higher tumor expression in STAD, CHOL and UCEC. The STAD box plot shows higher RPS23P6 RNA expression in tumor versus normal tissue (log2 FC = +0.478, t-test p = .006).
This table shows molecular features associated with RPS23P6 in patient tissues and cancer cell lines. In patient samples, RPS23P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
